Neurocrine Biosciences Inc (NAS:NBIX)
$ 141.56 -0.44 (-0.31%) Market Cap: 14.25 Bil Enterprise Value: 13.60 Bil PE Ratio: 39.00 PB Ratio: 5.97 GF Score: 89/100

Neurocrine Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 07:15PM GMT
Release Date Price: $107.99 (-12.22%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

All right. Let's go ahead and get started. Thanks, everyone, for coming. This is the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my colleagues, Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Neurocrine, and presenting on behalf of the company, we have CEO, Kevin Gorman. Kevin?

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you, Anupam, and thank you, everyone, for being here today. I almost feel like I need to be running back and forth on here. Before I get started, I put up our safe harbor statement. I will be making forward-looking statements. What I want to accomplish this morning is to tell you about Neurocrine, how we -- what we look like today, what our philosophy is, what our strategy has been, that's got us here and where we see that strategy taking us throughout the rest of this decade.

And so if you look at what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot